NCT06038682View on ClinicalTrials.gov

Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

December 31, 2023

Conditions
ARDSCOVID-19
Interventions
DRUG

Argatroban Injection

Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.

DRUG

Heparin

Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.

Trial Locations (1)

70852

University Hospital Ostrava, Ostrava

All Listed Sponsors
lead

University Hospital Ostrava

OTHER

NCT06038682 - Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure | Biotech Hunter | Biotech Hunter